I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma

Sato, Yuya; Kurosawa, Hidemitsu; Fukushima, Keitaro; Okuya, Mayuko; Hagisawa, Susumu; Sugita, Kenichi; Arisaka, Osamu; Inaki, Anri; Wakabayashi, Hiroshi; Nakamura, Ayane; Fukuoka, Masayoshi; Kayano, Daiki; Kinuya, Seigo

doi:10.1186/1824-7288-38-53

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, Goi et al . reported successful tandem autologous‐cord blood SCT in three patients with advanced neuroblastoma with amplified MYCN , whereas MIBG therapy with myeloablative CBT to recurrent neuroblastoma was described . Although several reports suggested that cord blood includes anti‐tumor effector cells against neuroblastoma, those reports did not elaborate on KIR‐ligand mismatches …”

Section: Discussionmentioning

confidence: 99%

“…Conversely, Goi et al 24 reported successful tandem autologous-cord blood SCT in three patients with advanced neuroblastoma with amplified MYCN, whereas MIBG therapy with myeloablative CBT to recurrent neuroblastoma was described. 25 Although several reports suggested that cord blood includes anti-tumor effector cells against neuroblastoma, those reports did not elaborate on KIR-ligand mismatches. 26 Natural killer cells express inhibitory KIR on the cell surface, and NK cell alloreactivity in the setting of allogeneic transplantation is determined by the specificity of KIR on donor NK cells for the recipient major histocompatibility complex (MHC) class I.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in high‐risk neuroblastoma

Matsuno

Toyama

Akiyama

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

Background The prognosis of high‐risk neuroblastoma stage 4 with bone marrow metastasis, MYCN amplified, or refractory neuroblastoma is poor. To date, no standard treatment has been established. In four selected cases, we challenged the killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in graft‐versus‐host disease (GVHD) with reduced‐intensity conditioning. Methods Prior to this study, conventional chemotherapy, autologous peripheral blood stem cell transplantation with high‐dose chemotherapy (busulfan and melphalan), surgery and radiation therapy were completed in every case. The status before cord blood transplantation in two cases was not complete remission (CR) and in the others it was CR. The primary site was the mediastinum, two adrenal glands and a retroperitoneum, respectively. Three patients had bone and bone marrow metastasis and one had MYCN amplification. In all cases, international neuroblastoma pathology classification was unfavorable histology. All patients were >2 years of age. Results Relapse occurred only in one patient 17 months after the last transplantation, and the other three patients maintained disease‐free survival for 74, 36, and 24 months, respectively. In one case of relapse the disease could be controlled by conventional chemotherapy. Except one, all patients had no severe complications, such as acute or chronic GVHD. One patient had gastric antral vascular ectasia and hemorrhagic cystitis. Conclusion This strategy might be feasible and should be investigated for efficacy in the future. No definite conclusion can be made, however, due to the very small number of patients. Further prospective studies are required to determine its efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in high‐risk neuroblastoma

Matsuno

Toyama

Akiyama

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…Some studies have recently reported the possibility to induce a graft-versus-tumor (GVT) effect against advanced neuroblastoma [ 55 – 57 ]. Two patients with relapsed neuroblastoma treated with I-131 MIBG and allo-HCT were reported in case reports from Japan [ 58 , 59 ]. A 6-year-old female with relapsed neuroblastoma received reduced-intensity allo-HCT 21 days after I-131 MIBG therapy [ 59 ].…”

Section: I-131 Mibg Therapy and Allogeneic Stem Cell Transplantatimentioning

confidence: 99%

“…Though no GVT effect was observed, the patient was in CR for 3 months after allo-HCT. A 5-year-old female with relapsed neuroblastoma was executed cord blood stem cell transplantation (CBSCT) 9 days after I-131 MIBG therapy and GVT effect was observed after CBSCT [ 58 ]. Normalization of both vanillylmandelic acid and homovanillic acid for 5 months and decrease of I-123 MIBG accumulations were maintained, although the patient died 12 months after CBSCT.…”

Section: I-131 Mibg Therapy and Allogeneic Stem Cell Transplantatimentioning

confidence: 99%

Iodine‐131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective

Kayano

Kinuya

2015

The Scientific World Journal

Self Cite

View full text Add to dashboard Cite

Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in childhood. The tumors express the norepinephrine (NE) transporters on their cell membrane and take in metaiodobenzylguanidine (MIBG) via a NE transporter. Since iodine-131 (I-131) MIBG therapy was firstly reported, many trails of MIBG therapy in patients with neuroblastoma were performed. Though monotherapy with a low dose of I-131 MIBG could achieve high-probability pain reduction, the objective response was poor. In contrast, more than 12 mCi/kg I-131 MIBG administrations with or without hematopoietic cell transplantation (HCT) obtain relatively good responses in patients with refractory or relapsed neuroblastoma. The combination therapy with I-131 MIBG and other modalities such as nonmyeloablative chemotherapy and myeloablative chemotherapy with HCT improved the therapeutic response in patients with refractory or relapsed neuroblastoma. In addition, I-131 MIBG therapy incorporated in the induction therapy was proved to be feasible in patients with newly diagnosed neuroblastoma. To expand more the use of MIBG therapy for neuroblastoma, further studies will be needed especially in the use at an earlier stage from diagnosis, in the use with other radionuclide formations of MIBG, and in combined use with other therapeutic agents.

show abstract

Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation

Kuroda

Wakabayashi

Araki

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma

Cited by 5 publications

References 10 publications

Killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in high‐risk neuroblastoma

Killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in high‐risk neuroblastoma

Iodine‐131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective

Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation

Contact Info

Product

Resources

About